JP2010518164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518164A5 JP2010518164A5 JP2009549615A JP2009549615A JP2010518164A5 JP 2010518164 A5 JP2010518164 A5 JP 2010518164A5 JP 2009549615 A JP2009549615 A JP 2009549615A JP 2009549615 A JP2009549615 A JP 2009549615A JP 2010518164 A5 JP2010518164 A5 JP 2010518164A5
- Authority
- JP
- Japan
- Prior art keywords
- sugar
- group
- galactose
- maltose
- fructose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 21
- 229930091371 Fructose Natural products 0.000 claims 21
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 21
- 239000005715 Fructose Substances 0.000 claims 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 21
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 21
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 21
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 21
- 229930182830 galactose Natural products 0.000 claims 21
- 229940074391 gallic acid Drugs 0.000 claims 21
- 239000008103 glucose Substances 0.000 claims 21
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 229940079593 drug Drugs 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000005155 neural progenitor cell Anatomy 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004793 anterograde amnesia Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004694 hippocampus damage Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000004766 neurogenesis Effects 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000009570 retrograde amnesia Diseases 0.000 claims 1
- 0 *c1ccc(C(C(C(c2c3*=C)=O)O)Oc2c(*)c(*)c3N)cc1C=[U] Chemical compound *c1ccc(C(C(C(c2c3*=C)=O)O)Oc2c(*)c(*)c3N)cc1C=[U] 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90123907P | 2007-02-14 | 2007-02-14 | |
| PCT/US2008/001914 WO2008147483A2 (en) | 2007-02-14 | 2008-02-13 | Neurogenic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518164A JP2010518164A (ja) | 2010-05-27 |
| JP2010518164A5 true JP2010518164A5 (OSRAM) | 2011-03-31 |
Family
ID=39763345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549615A Pending JP2010518164A (ja) | 2007-02-14 | 2008-02-13 | 神経性化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080227829A1 (OSRAM) |
| EP (2) | EP2117306A4 (OSRAM) |
| JP (1) | JP2010518164A (OSRAM) |
| CN (1) | CN101951768A (OSRAM) |
| AU (1) | AU2008257437A1 (OSRAM) |
| CA (1) | CA2677892A1 (OSRAM) |
| IL (1) | IL200383A0 (OSRAM) |
| RU (1) | RU2009134137A (OSRAM) |
| WO (1) | WO2008147483A2 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318737B2 (en) | 2009-09-02 | 2012-11-27 | Canthera Therapeutics Inc. | Compounds and compositions for treating cancer |
| US8349832B2 (en) * | 2009-09-02 | 2013-01-08 | Canthera Therapeutics | Compounds and compositions for treating cancer |
| AU2010289493A1 (en) | 2009-09-02 | 2012-04-19 | Canthera Therapeutics, Inc. | Compounds and compositions for treating cancer |
| CA3023725C (en) | 2009-10-22 | 2021-09-14 | Vizuri Health Sciences Llc | Methods of producing hydrated flavonoids and use thereof in the preparation of topical compositions |
| EP2629763B1 (en) | 2010-10-22 | 2017-12-06 | Vizuri Health Sciences LLC | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| WO2012172090A1 (en) | 2011-06-17 | 2012-12-20 | Ludwig Aigner | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders |
| CA2863158C (en) * | 2012-01-17 | 2021-02-02 | Suntory Holdings Limited | Glycosyltransferase gene and use thereof |
| JP6797408B2 (ja) * | 2014-11-06 | 2020-12-09 | 国立大学法人 長崎大学 | 新規アルツハイマー病治療薬 |
| JP6207545B2 (ja) * | 2015-04-30 | 2017-10-04 | 丸大食品株式会社 | 学習記憶能力増強剤 |
| JP6842093B2 (ja) * | 2019-08-20 | 2021-03-17 | 丸大食品株式会社 | 学習記憶能力増強剤 |
| JP7754447B2 (ja) * | 2021-10-21 | 2025-10-15 | 松本 忠昌 | ストレスを軽減するための組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9317071D0 (en) * | 1993-08-17 | 1993-09-29 | Univ Strathclyde | Flavonoids |
| GB9521184D0 (en) * | 1995-10-17 | 1995-12-20 | Univ Strathclyde | Flavonoids |
| US6297273B1 (en) * | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
| US5733926A (en) * | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
| US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
| CN1184895C (zh) * | 1998-07-16 | 2005-01-19 | 阿龙·塔博尔 | 大豆组合物及其促进健康的应用 |
| CA2345311A1 (en) * | 1998-09-24 | 2000-03-30 | Kazutoshi Watanabe | Hydroxyflavone derivatives as tau protein kinase 1 inhibitors |
| US6451837B1 (en) * | 1999-09-01 | 2002-09-17 | Andrius Baskys | Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors |
| US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| EP1127572A3 (en) * | 2000-02-25 | 2003-05-02 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| US6472436B1 (en) * | 2000-07-17 | 2002-10-29 | The Salk Institute For Biological Studies | Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production |
| JP4633897B2 (ja) * | 2000-08-17 | 2011-02-16 | 長瀬産業株式会社 | 神経突起伸長剤 |
| US6733797B1 (en) * | 2000-11-15 | 2004-05-11 | William K. Summers | Neuroceutical for improving memory and cognitive abilities |
| WO2002076473A1 (en) * | 2001-03-26 | 2002-10-03 | Academy Of Military Medical Sciences Institute Of Pharmacology And Toxicology | Quercetin derivative and its medicinal use |
| EP1417211B1 (en) * | 2001-07-27 | 2007-05-30 | Neptune Technologies & Bioressources Inc. | Natural phospholipids of marine origin containing flavonoids and polyunsaturated phospholipids and their uses |
| JP4609875B2 (ja) * | 2001-07-31 | 2011-01-12 | 有限会社大長企画 | 健康食品 |
| US9173866B2 (en) * | 2002-07-24 | 2015-11-03 | Children's Hospital Medical Center | Compositions and products containing R-equol, and methods for their making |
| US8138165B2 (en) * | 2002-10-22 | 2012-03-20 | Jenken Biosciences, Inc. | Chromones and chromone derivatives and uses thereof |
| US7763588B2 (en) * | 2003-06-13 | 2010-07-27 | The Salk Institute For Biological Studies | Method for increasing cognitive function and neurogenesis |
| WO2005020881A2 (en) * | 2003-09-01 | 2005-03-10 | Shanghai Comman Pharmaceutical Co. | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases |
| KR100610562B1 (ko) * | 2004-06-28 | 2006-08-08 | 재단법인서울대학교산학협력재단 | 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물 |
| US20060148727A1 (en) * | 2004-12-01 | 2006-07-06 | Curt Hendrix | Folate based composition for neurological and cognitive applications |
| US7442394B2 (en) * | 2005-05-02 | 2008-10-28 | University Of South Florida | Combined effects of nutrients on proliferation of stem cells |
| WO2008011538A2 (en) * | 2006-07-19 | 2008-01-24 | The Salk Institute For Biological Studies | Methods of using flavonoids to enhance memory |
-
2008
- 2008-02-13 CA CA002677892A patent/CA2677892A1/en not_active Abandoned
- 2008-02-13 US US12/069,861 patent/US20080227829A1/en not_active Abandoned
- 2008-02-13 JP JP2009549615A patent/JP2010518164A/ja active Pending
- 2008-02-13 WO PCT/US2008/001914 patent/WO2008147483A2/en not_active Ceased
- 2008-02-13 RU RU2009134137/21A patent/RU2009134137A/ru not_active Application Discontinuation
- 2008-02-13 AU AU2008257437A patent/AU2008257437A1/en not_active Abandoned
- 2008-02-13 CN CN200880011384XA patent/CN101951768A/zh active Pending
- 2008-02-13 EP EP08825828A patent/EP2117306A4/en not_active Withdrawn
- 2008-02-13 EP EP12165032A patent/EP2478901A3/en not_active Withdrawn
-
2009
- 2009-08-13 IL IL200383A patent/IL200383A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518164A5 (OSRAM) | ||
| Buccellato et al. | Treatment of Alzheimer’s disease: beyond symptomatic therapies | |
| Cheung et al. | Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia | |
| Trimmel et al. | S (+)-ketamine: current trends in emergency and intensive care medicine | |
| Zhu et al. | Risks associated with misuse of ketamine as a rapid-acting antidepressant | |
| NZ785712A (en) | Neuroactive steroids, compositions, and uses thereof | |
| US9956206B2 (en) | Compositions and methods for treating amyotrophic lateral sclerosis in responders | |
| WO2012125830A3 (en) | Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2013541583A5 (OSRAM) | ||
| BRPI0804623B8 (pt) | uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos | |
| RU2009134137A (ru) | Нейрогенные соединения | |
| JP2010513250A5 (OSRAM) | ||
| Gu et al. | Application of advanced technologies—nanotechnology, genomics technology, and 3D printing technology—in precision anesthesia: a comprehensive narrative review | |
| Aminnejad et al. | Comparing the efficacy and safety of dexmedetomidine/ketamine with propofol/fentanyl for sedation in colonoscopy patients: a doubleblinded randomized clinical trial | |
| Bruggisser et al. | Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets | |
| RU2013112890A (ru) | Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| CN105287518A (zh) | 一种克服术后睡眠障碍的药物组合物 | |
| JP2018530612A5 (OSRAM) | ||
| Salinas Salmeron et al. | Effects site concentrations of propofol using target-controlled infusion in dental treatment under deep sedation among different intellectual disability types | |
| CN110831590A (zh) | 含有培马贝特的医药 | |
| Kurdi et al. | Ketamine: a convulsant? | |
| Aan het Rot et al. | Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder. | |
| Mishra | A Comparative Evaluation Of Intranasal Midazolam-Ketamine Combination With Midazolam-Fentanyl Combination For Procedural Sedation In Pediatric Dental Patients | |
| Sha et al. | ED50 and ED90 of intravenous hydromorphone in ICU patient without mechanical ventilation: A Prospective Dose-Finding Study Using Up-and-Down Sequential Allocation Method |